CAS: 114077-82-6; 4-Chloronicotinaldehyde

相似化合物

10177-29-4 89284-61-7 189449-41-0

上下游产品

CAS号626-61-9 4-氯吡啶 | CAS号68-12-2 N,N-二甲基甲酰胺 | CAS号109-94-4 甲酸乙酯 | CAS号7379-35-3 4-氯吡啶盐酸盐 | CAS号69045-79-0 2-氯-5-碘吡啶 | CAS号2591-86-8 1-甲酰哌啶 | CAS号189449-41-0 4-氯-3-吡啶甲醇 | CAS号82257-15-6 4-甲氧基-3-吡啶甲醛 | CAS号10177-29-4 4-氯烟酸 | CAS号189449-41-0 4-氯-3-吡啶甲醇 | CAS号823189-18-0 1-(4-chloropyri... | CAS号86236-37-5 噻吩并[3,2-c]吡啶-2-羧酸 | CAS号471909-43-0 (E)-4-氯烟碱甲醛肟 | CAS号478149-07-4 噻吩并[3,2-c]吡啶-2-羧酸甲酯

4-氯吡啶 反应生成4-氯吡啶-3-甲醛
参考文献:Wo2008/49855
标题:Wo2008/49855

专利信息

专利号:US-7754188-B2
优先权日:2003-06-30
标 题:Radiolabeled cannabinoid-1 receptor modulators
发明人：BURNS H DONALD; CHEN ALEX M; GIBSON RAYMOND E; GOULET MARK T; HAGMANN WILLIAM K; HAMILL TERENCE G; JEWELL JAMES P; LIN LINUS S; LIU PING; PERESYPKIN ANDREY V
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.

专利号:US-9695191-B2
优先权日:2009-08-05
标题 :Conformationally constrained, fully synthetic macrocyclic compounds
发明人：OBRECHT DANIEL; ERMERT PHILIPP; OUMOUCH SAID; LACH FRANCK; LUTHER ANATOL; MARX KARSTEN; MÖHLE KERSTIN
权利人:OBRECHT DANIEL; ERMERT PHILIPP; OUMOUCH SAID; LACH FRANCK; LUTHER ANATOL; MARX KARSTEN; MÖHLE KERSTIN; POLYPHOR AG
摘要:Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of type (I) are constituted by three distinct building blocks: an aromatic template a, a conformation modulator b and a spacer moiety c as detailed in the description and the claims. Macrocycles of type (I) are readily manufactured by parallel synthesis or combinatorial chemistry. They are designed to interact with specific biological targets. In particular, they show agonistic or antagonistic activity on the motilin receptor (MR receptor), on the serotonin receptor of subtype 5-HT 2B (5-HT 2B receptor), and on the prostaglandin F2•receptor (FP receptor). They are thus potentially useful for the treatment of hypomotility disorders of the gastrointestinal tract such as diabetic gastroparesis and constipation type irritable bowl syndrome; of CNS related diseases like migraine, schizophrenia, psychosis or depression; of ocular hypertension such as associated with glaucoma and preterm labour.